Background & Aims There is controversy over whether use of non-vitamin K antagonist oral
anticoagulants (NOACs) associates with increased risk of major gastrointestinal bleeding …

It is well known that diabetes is a prominent risk factor for cardiovascular (CV) events. The
level of CV risk depends on the type and duration of diabetes, age and additional co …

Randomized controlled trials (RCTs) are preferred by payers for health technology
assessments and coverage decisions. However, the inclusion of a highly selective patient …

Aims To assess the effectiveness and safety of rivaroxaban versus warfarin for the
prevention of major adverse cardiovascular events (MACE) and major adverse limb events …

Objective This study incorporates the results of subgroup analyses of currently published
randomized controlled trials (RCTs) and real-world cohort studies to compare the …

Background Patients with warfarin have a potential risk of warfarin-related nephropathy,
which could result in the discontinuation of anticoagulation therapy. The question of whether …

Purpose We evaluated the generalizability and accuracy of the IBM® MarketScan® Health
Risk Assessment (HRA) data to assess its suitability as supplement to linked claims data …

Objective To address gaps in the data comparing non–vitamin K antagonist oral
anticoagulants (NOACs) and warfarin among patients with nonvalvular atrial fibrillation …

Diabetes mellitus (DM) is a chronic metabolic disease which is independently associated
with unfavorable clinical outcomes in patients with atrial fibrillation (AF). Few real-world data …

Aims To evaluate the effectiveness and safety of apixaban versus rivaroxaban among
patients with nonvalvular atrial fibrillation (NVAF) and type 2 diabetes mellitus (T2DM) …